Pharma procurement teams are being asked to do something that sounds simple—and is anything but: “Just buy the drug cheaper.”
But the real question isn’t the unit price on a PO. It’s the total cost of ownership (TCO): the full, end-to-end cost of getti…
The Real Price of a Drug: A Total Cost of Ownership Model for Pharma Procurement Teams Read Post »
Pharma doesn’t just invent drugs. It also buys time.
That’s the real story behind drug patent term extensions—and why they can turn “extra time” into billions in revenue. In a world where blockbuster exclusivity is the difference between a life-changin…
Drug Patent Term Extensions: How Pharma Turns Extra Time Into Billions Read Post »
Generic drugmakers don’t “wait their turn.” They litigate their way to the starting line.
If you’ve ever wondered how some generic companies manage to launch earlier than the public expects, the answer is often hiding in plain sight: the Hatch-Waxman f…
The quiet shift in pharma contracting: “abuse-deterrent” isn’t just a label claim anymore—it’s a procurement strategy.
Drug patent cliffs don’t just threaten revenue—they reshape how payers, pharmacy benefit managers, and government formularies decide …
Old Drugs, New Signals: What the Side-Effect Conversation Is Really Saying
The side-effect conversation is getting louder—and it’s not just about safety.
For years, “old drugs” were treated like finished products: approved, prescribed, and largely file…
Old Drugs, New Signals: What the Side-Effect Conversation is Really Saying Read Post »
A drug patent isn’t “worth” what the market says—it’s worth what it costs to defend.
In pharma M&A, investors love clean narratives: a pipeline, a blockbuster, a patent portfolio that “supports valuation.” But the real math often lives somewhere da…
What a Drug Patent Is Really Worth: How Litigation Costs Reshape Acquisition Value Read Post »
Most NDAs Don’t Fail on Science. They Fail on Strategy.
In pharma, we love to talk about molecules—mechanisms, trial design, endpoints, and the elegance of the data. But anyone who’s shepherded an NDA knows the uncomfortable truth: the submission is …
Two clocks. One drug. And a lot of investors who think they’re watching the wrong one.
In pharma, timing isn’t just strategy—it’s survival. Yet many teams (and plenty of outside observers) still treat “patent expiry” as the finish line. It isn’t.
A rec…
Advil Dual Action, a pain relief medication combining ibuprofen and aspirin, is designed to provide fast and effective relief… https://www.Drugchatter.com/chat/61409/how-quickly-does-advil-dual-action-work/
DrugChatter: How quickly does advil dual action work? Read Post »
Small molecules vs. biologics: the patent playbook for generics vs. biosimilars is not just different—it’s fundamentally strategic.
If you’re building a drug patent portfolio—or planning for generic or biosimilar entry—you already know the headline: sm…
Get new actionable insights and updates from BiotechBlog
